Follica has been beavering away at their hair loss cure for some time. Now they have announced the results of Phase II Testing and may just have something really exciting on their hands. We look closer.
FDA Approval Marques
The FDA has only ever approved two hair loss medications for the treatment of androgenetic alopecia. They do not work at all for many who try them and come with the potential for unwanted side-effects. Indeed, one of those side-effects means that only one of the medications is available to women in oral form.
In terms of efficacy, for those who do benefit, users can hope to halt the progress of their hair loss. For some, there will even be some new growth. When it comes to measuring new growth, for testing purposes, there is an accepted level of improvement. An amount of new hair that qualifies the treatment as meaningful and worthy of the FDA approval.
For decades, that level of improvement has been 12%. It is the improvement available from both currently FDA approved treatments. It is also one of the reasons why many find the treatments underwhelming in terms of results.
Follica Hair Loss Cure
The team at Follica, based in Boston MA, has been working on a piece of technology developed at the University of Pennsylvania. It aims to break the mould and offer a hair loss treatment capable of delivering visible results.
How It Works:
Their technology deliberately disrupts the scalp during a brief, five minutes, session. The team then treat the wounds with a cocktail that aims to encourage the growth of new hairs.
The biology behind it is fairly simple to understand, though the devil is most definitely in the detail. The disrupted cells attract cells that migrate to the site to assist with healing. When they arrive those cells have a decision to make, should I be an epidermis cell or should I create new hair? The team is working on that small window of opportunity, targetting a number of biological pathways aiming to push the decision towards making hair.
Hair Loss Test Results
You might think that a trial, setting out to achieve a benchmark of a 12% improvement, could begin with some optimism. But consider that in the last four decades only two drugs have achieved that mark and made it to market with FDA approval. So any team achieving that mark has done something rarely achieved before. Any team producing results higher than that have made a newsworthy impact on the challenging world of hair loss.
As is normal in Phase II testing, the patient group of 48 subjects was tested using varying dosages. The average improvement, measured by the increase in visible new non-vellus hairs, across all the test groups was a staggering 29%. The group that received what Follica is calling ‘best performing’ actually achieved 44% over the 3-month trial.
HIS Hair Clinic
We are not given to fits of excitement over this sort of thing. We read far too many of them. But make no mistake this is a stunning piece of news. 44% is not just an improvement on a 12% benchmark that has stood for decades. It is the difference between knowing yourself that you are doing something about your hair loss and the results being instantly visible to others.
Phase III trials are expected next year so we have a little time to wait before a product is on the horizon. But Follica has given the disrupting device a name, the Hair Follicle Neogenesis (HFN). And they have a global agreement signed with the University of Pennsylvania to market. We will be watching closely.
If you would like to discuss your hair loss situation with one of our friendly team of experts simply complete the contact form at the side of this page, or click here to find your nearest clinic.